Protagonist Therapeutics, Inc (PTGX) stock
PTGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 12/30199% above fair value
$124.67−0.16 (-0.13%)
Close on Nov 17, 2026Market cap $8.07BP/E 121.0Yield –
Protagonist Therapeutics profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Protagonist Therapeutics's profit margin for the twelve months ending Jun 30, 2026 was 29.4%. For fiscal 2025 it was -282.8%, against 63.3% the year before. The highest annual figure on record is 63.3% in fiscal 2024.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -282.8% | −346.2 |
| FY2024 | Dec 31, 2024 | 63.3% | +194.9 |
| FY2023 | Dec 31, 2023 | -131.6% | +347.7 |
| FY2022 | Dec 31, 2022 | -479.3% | −20.3 |
| FY2021 | Dec 31, 2021 | -458.9% | −227.9 |
| FY2020 | Dec 31, 2020 | -231.1% | +33183.2 |
| FY2019 | Dec 31, 2019 | -33414.3% | −33288.4 |
| FY2018 | Dec 31, 2018 | -125.9% | +58.3 |
| FY2017 | Dec 31, 2017 | -184.2% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 76.3% | +703.2 |
| Q1 FY2026 | Mar 31, 2026 | 6.7% | +47.9 |
| Q4 FY2025 | Dec 31, 2025 | -596.8% | −674.0 |
| Q3 FY2025 | Sep 30, 2025 | -834.9% | −124.5 |
| Q2 FY2025 | Jun 30, 2025 | -627.0% | +107.8 |
| Q1 FY2025 | Mar 31, 2025 | -41.2% | −122.5 |
| Q4 FY2024 | Dec 31, 2024 | 77.2% | +31.6 |
| Q3 FY2024 | Sep 30, 2024 | -710.4% | +4066.9 |
| Q2 FY2024 | Jun 30, 2024 | -734.7% | −653.4 |
| Q1 FY2024 | Mar 31, 2024 | 81.3% | +509.6 |
| Q4 FY2023 | Dec 31, 2023 | 45.6% | +374.2 |
| Q2 FY2022 | Jun 30, 2022 | -4777.3% | −3415.6 |
| Q1 FY2022 | Mar 31, 2022 | -81.4% | +306.4 |
| Q4 FY2021 | Dec 31, 2021 | -428.3% | −94.0 |
| Q3 FY2021 | Sep 30, 2021 | -328.6% | −269.4 |
| Q2 FY2021 | Jun 30, 2021 | -1361.7% | −718.0 |
| Q1 FY2021 | Mar 31, 2021 | -387.8% | +8.5 |
| Q4 FY2020 | Dec 31, 2020 | -334.3% | +569.8 |
| Q3 FY2020 | Sep 30, 2020 | -59.2% | +530.1 |
| Q4 FY2019 | Dec 31, 2019 | -643.7% | −500.9 |
| Q3 FY2019 | Sep 30, 2019 | -396.3% | −322.0 |
| Q1 FY2019 | Mar 31, 2019 | -904.0% | −833.0 |
| Q4 FY2018 | Dec 31, 2018 | -589.2% | −562.2 |
| Q3 FY2018 | Sep 30, 2018 | -142.8% | −87.9 |
| Q2 FY2018 | Jun 30, 2018 | -74.2% | – |
| Q1 FY2018 | Mar 31, 2018 | -71.1% | – |
| Q4 FY2017 | Dec 31, 2017 | -27.1% | – |
| Q3 FY2017 | Sep 30, 2017 | -54.9% | – |
See a number that looks wrong?